[1]朱晓琳,李强.肝腺瘤的影像诊断现状及进展[J].国际放射医学核医学杂志,2011,35(2):124-127.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
 ZHU Xiao-lin,LI Qiang.Status and advances in imaging diagnsis of hepatic adenoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):124-127.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
点击复制

肝腺瘤的影像诊断现状及进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第2期
页码:
124-127
栏目:
临床放射学
出版日期:
1900-01-01

文章信息/Info

Title:
Status and advances in imaging diagnsis of hepatic adenoma
作者:
朱晓琳1 李强2
1. 300060 天津, 天津医科大学附属肿瘤医院超声诊断治疗科;
2. 300060 天津, 天津医科大学附属肿瘤医院肝胆外科
Author(s):
ZHU Xiao-lin1 LI Qiang2
Department of Ultrasound, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
关键词:
腺瘤肝细胞体层摄影术X线计算机磁共振成像超声检查正电子发射断层显像术
Keywords:
Adenomaliver cellTomographyX-ray computedMagnetic resonance imagingUltrasonographyPositron-emission tomography
DOI:
10.3760/cma.j.issn.1673-4114.2011.02.014
摘要:
肝腺瘤是罕见的肝脏良性肿瘤,由于缺乏特征表现,临床很容易误诊。近年来随着影像学技术的飞速发展,肝腺瘤的检出率逐年增高。该文综合国内外文献,对肝腺瘤的影像学诊断特征作综述,以期提高临床及放射科医生对肝腺瘤的认识,辅助临床正确诊断肝腺瘤。
Abstract:
Hepatic adenoma is a rare benign tumor, which is quite easily misdiagnosed for its nonspecific appearance. The great advances in imaging technology have led an increase in the detection rate of hepatic adenoma. This article reviews the recent advances at home and abroad in imaging diagnostic characteristic of hepatic adenoma, in order to raise awareness of clinicians and make accurate judgment.

参考文献/References:

[1] Grazioli L, Federle M P, Brancatelli G,et al. Hepatic adenomas:imaging and pathologic findings. Radiographics,2001, 21(4):877-892.
[2] 许达生,陈君录,黄昭民.临床CT诊断学.广州:广东科技出版社,1998.
[3] Ednaondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med, 1976, 294(9):470-472.
[4] 正辉,黄志强,董家鸿.亚临床肝癌.北京:军事医学科学出版社,2003.
[5] 彭利,王顺祥,张风瑞.肝细胞腺瘤的诊断和治疗.中华肝胆外科杂志,2002,8(12):721-722.
[6] 金乃善,唐光健.肝细胞腺瘤的CT诊断(附三例报告).中华放射学杂志,1995,29(5):335-337.
[7] Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure:Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg, 2005,129(6):1348-1352.
[8] Chaib E, Gama-Rodrigues J, Ribeiro MA Jr, et al. Hepatic adenoma. Timing for surgery. Hepatogastroenterology, 2007, 54(77):1382-1387.
[9] 叶彩儿,陈伟建,叶民,等.CT检查肝腺瘤误诊4例报告(结合文献17例分析).浙江临床医学,2005,7(6):649-650.
[10] 叶慧义,郭智萍,李俊来,等.肝腺瘤的综合影像诊断.中华放射学杂志,2002,36(2):156-158.
[11] 梁晓辉,杨予川,杨庆艳,等.肝腺瘤的CT诊断与鉴别.黑龙江医学,2007,31(6):415-416.
[12] Bioulac-Sage P, Balabaud C, Wanless IR. Diagnosis of focal nodular hyperplasia:not so easy. Am J Surg Pathol, 2001,25(10):1322-1325.
[13] Grazioli L, Morana G, Kirchin MA, et al, Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumiue-enhanced MR imaging:prospective study. Radiology, 2005, 236(1):166-177.
[14] Corot C, Robert P, Idée JM, et al. Recent advances in iron oxid nanoctystal technology for medical imaging. Adv Drug Deliv Rev, 2006, 58(14):1471-1504.
[15] Daldrup-Link HE, Rydland J, Helbich TH, et al. Quantification of breast tumor mirovascular permeability with femglneose-enhanced MR imaging:initial phase II multicellular trial. Radiology, 2003, 229(3):885-892.
[16] Beets-Tan RG, Van Engelshoven JM, Greve JW. Hepatic adenoma andfocal nodular hyperplasia:MR findings with superparamagnetic iron oxide-enhanced MRI. Clin Imaging, 1998, 22(3):211-215.
[17] Ba-Ssalamah A, Uffmann M, Saini S, et al. Clinical value of MRI liver-specific contrast agents:a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol, 2009, 19(2):342-357.
[18] Stroszezynski C, Gaffke G, Gretschel S, et al. Use of SPIO-enhanced T1-and T2-weighted images for the diferentiation of liver lesions:an ROC analysis. Rofo, 2003, 175(10):1368-1375.
[19] King LJ, Burkill GJC, Scurf ED. MnDPDP enhanced magnetic resonance imaging ofocal liver lesions. Clin Radiol, 2002, 57(12):1047-1057.
[20] Kim MJ, Kim JH, Lira JS, et al. Detection and characterization of focal hepatic lesions:mangafodipir vs. superparamagnetic iron oxide-enhanced magnetie resonance imaging. J Magn Reson Imaging, 2004, 20(4):612-621.
[21] Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaglng:correlation with histopathologic findings and spiral CT-initial observations. Radiology, 2005, 234(2):468-478.
[22] 刘丽华,祁吉.新型肝脏MRI对比剂对肝细胞腺瘤诊断与鉴别诊断的价值.国外医学放射学杂志,2008,31(2):118-121.
[23] Macarini L, Marini S, Milillo P, et al. Double-corltrast MRI (DC-MRI) in the study of the cirrhotic liver:utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions. Radiol Med, 2006, 111(8):1087-1102.
[24] 杨建秀,王从光,于卫中,等.肝腺瘤的超声表现.医学创新研究,2006,3(11):127.
[25] 龙花.B超诊断肝腺瘤10例报告.世界今日医学杂志,2005,6(3):191-192.
[26] Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics, 2004, 24(4):921-935.
[27] Kim TK, Jang HJ, Wilson SR. Benign liver masses:imaging with microbubble contrast agents. Ultrasound Q, 2006, 22(1):31-39.
[28] Kim TK, Jang HJ, Burns PN, et al. Focal nodular hyperplasia and hepatic adenoma:differentiation with low-mechanical-index contrast-enhanced sonography. AJR Am J Roentgenol,2008,190(1):58-66.
[29] Dietrich CF, Sehuessler G, Trojan J, et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol, 2005, 78(932):704-707.
[30] 卢光明,陈君坤.CT诊断与鉴别诊断.南京:东南大学出版社,1999.
[31] Kume N, Suga K, Nishigauchi K, et al. Characterization of hepatic adenoma with atypical appearance on CT and MRI by radionuelide imaging. Clin Nucl Med, 1997, 22(12):825-831.
[32] Magini G, Farsad M, Frigerio M, et al. C-11 acetate oesnot enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med, 2009, 34(10):659-665.

相似文献/References:

[1]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
 Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[2]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
 Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[3]黎昕,代海洋,钟华,等.十二指肠Brunner腺腺瘤的CT表现(附7例病例报道)[J].国际放射医学核医学杂志,2015,39(3):239.[doi:10.3760/cma.j.issn.1673-4114.2015.03.011]
 Li Xin,Dai Haiyang,Zhong Hua,et al.CT imaging features of duodenal Brunner’s gland adenoma(with 7 cases analysis)[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):239.[doi:10.3760/cma.j.issn.1673-4114.2015.03.011]
[4]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
 ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[5]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
 LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[6]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
 ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):23.
[7]周云,刘璐,宋进华.经肝动脉灌注90Y微球治疗肝癌的研究进展[J].国际放射医学核医学杂志,2006,30(6):321.
 ZHOU Yun,LIU Lu,SONG Jin-hua.Clinical researched progress of intra-arterial radioembolization with 90Y-glass microspheres for treatment of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):321.
[8]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
 Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
[9]赵竞,张占文,马慧,等.PET/CT显像剂18F-氟丙酸在肝癌中的生物学评估[J].国际放射医学核医学杂志,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
 Zhao Jing,Zhang Zhanwen,Ma Hui,et al.Biological evaluation of PET/CT imaging agent 18F-fluoropropionic acid in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
[10]陈佩和,徐文贵,李小凤,等.肝细胞肝癌的葡萄糖代谢机制及在PET显像中的应用价值[J].国际放射医学核医学杂志,2018,(6):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]
 Chen Peihe,Xu Wengui,Li Xiaofeng,et al.Glycometabolism mechanism in hepatocellular carcinoma and its application in PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]

备注/Memo

备注/Memo:
收稿日期:2011-01-20。
通讯作者:李强,Email:liqiang4016@yahoo.com
更新日期/Last Update: 1900-01-01